Reuters

06 Jun 2026, 18:49 UTC · 3h ago

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

Read original · https://www.reuters.com/business/healthcare-pharmaceuticals/dexcoms-glucose-monitor-use-shows-benefit-non-insulin-diabetic-patients-study-2026-06-06/

Top 1 mover · tap to explore

Story key points

1 claims · impact-rated

What matters in this story

1
Dexcom's G7 continuous glucose monitor improved blood sugar control in type 2 diabetes patients not using insulin compared to routine care. — Positive clinical outcomes for a non-insulin using patient population significantly expand the addressable market and potential adoption rate for the device.
+0.60

Ticker attribution

Model heads

Sentiment in this article

DXCM+0.80
Study results show its G7 monitor improved blood sugar control in type 2 diabetes patients.

Relationships in this article

No ticker relationship head found.

Early access

You’re reading about it. Someone else is already positioned.

News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.

DXCM

Browse live screenings

Impact vectors

6 related stories

Business Wire
3h ago
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- diabetes
- glucose monitoring
- healthcare
Read

Dexcom's glucose monitor use shows benefit in non-insulin diabetic pa… · News Impact Screener

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i